Placebo | Lasmiditan 50 mg | Lasmiditan 100 mg | Lasmiditan 200 mg | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
PF | MP | CM/S | PF | MP | CM/S | PF | MP | CM/S | PF | MP | CM/S | |
Outcome(s) | N = 180 | N = 239 | N = 414 | N = 135 | N = 138 | N = 160 | N = 274 | N = 267 | N = 243 | N = 324 | N = 220 | N = 235 |
MBS freedom, n (%) | 168 (93.3) | 98 (41.0)* | 42 (10.1)* | 126 (93.3) | 60 (43.5)* | 19 (11.9)* | 249 (90.9) | 131 (49.1)* | 23 (9.5)* | 296 (91.4) | 99 (45.0)* | 24 (10.2)* |
Functional disability freedoma, n (%) | 166 (92.2) | 34 (14.2)* | 3 (0.7) | 124 (91.9) | 20 (14.5)* | 1 (0.6) | 240 (87.6) | 34 (12.7)* | 4 (1.6) | 265 (81.8) | 28 (12.7)* | 4 (1.7) |
PGIC (much better/very much better), n (%) | 159 (88.3) | 65 (27.2)* | 7 (1.7) | 117 (86.7) | 52 (37.7)* | 2 (1.3) | 243 (88.7) | 84 (31.5)* | 5 (2.1) | 271 (83.6) | 71 (32.3)* | 4 (1.7) |
Both MBS freedom and disability freea, n (%) | 161 (89.4) | 27 (11.3)* | 1 (0.2) | 119 (88.1) | 16 (11.6)* | 0 (0.0) | 228 (83.2) | 28 (10.5)* | 2 (0.8) | 255 (78.7) | 22 (10.0)* | 0 (0.0) |
MBS freedom, disability freedoma, and PGIC (much better/very much better), n (%) | 145 (80.6) | 16 (6.7)* | 1 (0.2) | 107 (79.3) | 13 (9.4)* | 0 (0.0) | 208 (75.9) | 20 (7.5)* | 1 (0.4) | 223 (68.8) | 15 (6.8)* | 0 (0.0) |